Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor
about
PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancerThe non-genomic crosstalk between PPAR-gamma ligands and ERK1/2 in cancer cell linesPeroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinomaDifferentiation therapy of leukemia: 3 decades of development.Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.PPAR-gamma receptor ligands: novel therapy for pituitary adenomas.Peroxisome proliferator-activated receptors and cancer: challenges and opportunitiesA Role for PPARgamma in the Regulation of Cytokines in Immune Cells and Cancer.A Novel Mechanism of PPARgamma Regulation of TGFbeta1: Implication in Cancer BiologyRole of peroxisome proliferator-activated receptor gamma and its ligands in the treatment of hematological malignanciesThe Role of PPAR Ligands in Controlling Growth-Related Gene Expression and their Interaction with Lipoperoxidation Products.Pharmacological exploitation of the peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents.Effects of PPARγ Ligands on Leukemia.Effect of thiazolidinediones on the erythropoeitic and germinal cells in the male wistar rats.15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells.Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma ) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity.PPAR-gamma Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors.Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists.Can an oral antidiabetic (rosiglitazone) be of benefit in leukemia treatment?Rosiglitazone suppresses glioma cell growth and cell cycle by blocking the transforming growth factor-beta mediated pathway.Rosiglitazone inhibits proliferation of renal proximal tubular cells via down-regulation of ERK and Akt.Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells.Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways.Peroxisome proliferator activated receptor-γ and the ubiquitin-proteasome system in colorectal cancer.Ligand activation of peroxisome proliferator-activated receptor gamma induces apoptosis of leukemia cells by down-regulating the c-myc gene expression via blockade of the Tcf-4 activity.Troglitazone induces G1 arrest by p27(Kip1) induction that is mediated by inhibition of proteasome in human gastric cancer cells.Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas.Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells.Suppressive effects of lycopene and β-carotene on the viability of the human esophageal squamous carcinoma cell line EC109.
P2860
Q21328702-FCA42FD7-C387-4666-8F04-CA557708CEE6Q28238709-F100FF20-178E-400F-85A3-ED97A8787C03Q28366616-3C55B6B2-4665-43F3-880F-5384B7BB32F3Q33409795-A808BDC7-F26C-4F51-AB22-30908AC6BBECQ33692555-A5187BC8-32A0-4E1B-BAAC-9330F793F6A6Q34985044-FDD9CF4D-6AFD-46A6-979B-C11672E2AD32Q35210023-BCBD2A71-ED42-42F2-AC60-5F16E4CB6A44Q36724717-989EA112-85E1-4029-99DD-45B7374ED015Q36743890-12719DF6-9761-4C50-B3C2-AD28CFE32A9FQ37182794-33B70664-F9A9-4F75-9ADB-FFA4E0CD129CQ37211832-CF8C0459-5239-4440-9658-1DE8B4F55ECEQ37512921-F2A517EE-43C1-4C0E-A8C4-37E6DC2DD2EAQ38017661-5678A567-9391-4811-A097-EAE85C31B5EAQ38260621-C02D9E0B-BB08-4221-9886-96FF2BA9D15DQ38292542-054F1922-B5A0-4181-846F-3488B182FBB8Q38359904-7128597B-09F0-48B8-8287-9B5714FC3151Q38620031-DC807B52-11DC-4B6D-8276-67D61562A301Q38785265-F66AB0EF-E381-42AE-94D6-A2A7D495FC73Q38909191-2AFA3E01-1C04-4E0A-A07E-5B3FCDD0745FQ39329694-870BCBE5-1F1E-46E9-8A2B-2C4033EFB259Q39746277-4BA58A5C-76FB-4A02-A834-45EEC5C0078CQ40387584-F5DD1CC9-A5F3-4093-B0F6-86EEF946E57FQ40769938-B19566D1-8FBD-482B-AFD5-0EC309443543Q41144730-93F90CDA-B930-4CF7-990C-7A30C98B3517Q43970140-85D8C0E8-A724-4D2A-9168-B2BF2A5A689FQ44083584-118A2E4A-22D7-40FA-B0C3-6F1042B51E70Q44179348-8D5B48CC-3070-4D8F-B825-22A5FB2988DBQ44830451-5AB1E2B4-594A-43F2-90FB-FFA34C69BFE4Q55254356-8F058F8F-F129-4867-B4A3-322ECF015562
P2860
Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Troglitazone suppresses cell g ...... lin-dependent kinase inhibitor
@ast
Troglitazone suppresses cell g ...... lin-dependent kinase inhibitor
@en
Troglitazone suppresses cell g ...... lin-dependent kinase inhibitor
@nl
type
label
Troglitazone suppresses cell g ...... lin-dependent kinase inhibitor
@ast
Troglitazone suppresses cell g ...... lin-dependent kinase inhibitor
@en
Troglitazone suppresses cell g ...... lin-dependent kinase inhibitor
@nl
prefLabel
Troglitazone suppresses cell g ...... lin-dependent kinase inhibitor
@ast
Troglitazone suppresses cell g ...... lin-dependent kinase inhibitor
@en
Troglitazone suppresses cell g ...... lin-dependent kinase inhibitor
@nl
P2093
P356
P1476
Troglitazone suppresses cell g ...... lin-dependent kinase inhibitor
@en
P2093
A Sugimura
H Tsuchiya
Y Kiriyama
Y Sakurada
Y Tokumitsu
P356
10.1006/BBRC.1999.1049
P407
P577
1999-08-11T00:00:00Z